Literature DB >> 28575321

The Validity and Sensitivity of PANSS-6 in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Study.

Søren D Østergaard1,2, Leslie Foldager3,4, Ole Mors1,2, Per Bech5, Christoph U Correll6,7,8.   

Abstract

It was recently demonstrated in acutely exacerbated schizophrenia that a 6-item version (PANSS-6: P1 = delusions, P2 = conceptual disorganization, P3 = hallucinations, N1 = blunted affect, N4 = social withdrawal, N6 = lack of spontaneity/flow of conversation) of the 30-item Positive and Negative Syndrome Scale (PANSS-30) was scalable (all items provide unique information regarding syndrome severity) and able to separate the effect of antipsychotics from placebo. Here, we tested the validity and sensitivity of PANSS-6 in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) outpatient study. We examined (1) the scalability of PANSS-6 and PANSS-30; (2) the correlation between PANSS-6 and PANSS-30 total scores; (3) whether PANSS-6 could identify symptom remission (Andreasen criteria); and (4) the effect of the 5 antipsychotics studied in CATIE Phase-1, using PANSS-6 and PANSS-30 total scores as outcomes. We found that for the 577 subjects with complete PANSS ratings at baseline, month 1, 3, and 6, PANSS-6 was scalable, whereas PANSS-30 was not. In the 1432 subjects in the intention-to-treat (ITT) sample, PANSS-6 and PANSS-30 total scores were highly correlated (Spearman correlation coefficient = 0.86). Based on 5080 ITT ratings, PANSS-6 identified symptom remission with an accuracy of 0.99 (95% confidence interval = 0.99-0.99). In ITT analyses, PANSS-6 and PANSS-30 identified the same statistically significant differences in antipsychotic efficacy, ie, olanzapine was superior to risperidone (P-value PANSS-6 = 0.0003 and PANSS-30 = 0.0003) and ziprasidone (P-value PANSS-6 = 0.0018 and PANSS-30 = 0.0046). In conclusion, PANSS-6 is a brief schizophrenia rating scale that adequately measures severity, remission, and antipsychotic efficacy related to core positive and negative symptoms in clinical trials. Prospective studies of PANSS-6 in clinical practice are required.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 28575321      PMCID: PMC5814988          DOI: 10.1093/schbul/sbx076

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN: 0586-7614            Impact factor:   9.306


  30 in total

1.  Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.

Authors:  Madhukar H Trivedi; A John Rush; Stephen R Wisniewski; Andrew A Nierenberg; Diane Warden; Louise Ritz; Grayson Norquist; Robert H Howland; Barry Lebowitz; Patrick J McGrath; Kathy Shores-Wilson; Melanie M Biggs; G K Balasubramani; Maurizio Fava
Journal:  Am J Psychiatry       Date:  2006-01       Impact factor: 18.112

2.  Measurements of response, remission, and recovery in schizophrenia and examples for their clinical application.

Authors:  Stefan Leucht
Journal:  J Clin Psychiatry       Date:  2014       Impact factor: 4.384

3.  The usefulness of rating scales in patients with schizophrenia.

Authors:  W Wolfgang Fleischhacker
Journal:  Acta Psychiatr Scand       Date:  2016-06       Impact factor: 6.392

4.  Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole Study Group.

Authors:  D L Zimbroff; J M Kane; C A Tamminga; D G Daniel; R J Mack; P J Wozniak; T B Sebree; B A Wallin; K B Kashkin
Journal:  Am J Psychiatry       Date:  1997-06       Impact factor: 18.112

Review 5.  Algorithms and collaborative-care systems for depression: are they effective and why? A systematic review.

Authors:  Mazda Adli; Michael Bauer; A John Rush
Journal:  Biol Psychiatry       Date:  2006-06-01       Impact factor: 13.382

6.  The Texas medication algorithm project: clinical results for schizophrenia.

Authors:  Alexander L Miller; M Lynn Crismon; A John Rush; John Chiles; T Michael Kashner; Marcia Toprac; Thomas Carmody; Melanie Biggs; Kathy Shores-Wilson; Judith Chiles; Brad Witte; Christine Bow-Thomas; Dawn I Velligan; Madhukar Trivedi; Trisha Suppes; Steven Shon
Journal:  Schizophr Bull       Date:  2004       Impact factor: 9.306

7.  Efficacy of an algorithm-guided treatment compared with treatment as usual: a randomized, controlled study of inpatients with depression.

Authors:  Michael Bauer; Andrea Pfennig; Michael Linden; Michael N Smolka; Peter Neu; Mazda Adli
Journal:  J Clin Psychopharmacol       Date:  2009-08       Impact factor: 3.153

8.  The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update.

Authors:  Troy A Moore; Robert W Buchanan; Peter F Buckley; John A Chiles; Robert R Conley; M Lynn Crismon; Susan M Essock; Molly Finnerty; Stephen R Marder; Del D Miller; Joseph P McEvoy; Delbert G Robinson; Nina R Schooler; Steven P Shon; T Scott Stroup; Alexander L Miller
Journal:  J Clin Psychiatry       Date:  2007-11       Impact factor: 4.384

9.  PANSS-6: a brief rating scale for the measurement of severity in schizophrenia.

Authors:  S D Østergaard; O M Lemming; O Mors; C U Correll; P Bech
Journal:  Acta Psychiatr Scand       Date:  2015-11-12       Impact factor: 6.392

10.  Assessing clinical and functional outcomes in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial.

Authors:  Marvin S Swartz; Diana O Perkins; T Scott Stroup; Joseph P McEvoy; Jennifer M Nieri; David C Haak
Journal:  Schizophr Bull       Date:  2003       Impact factor: 9.306

View more
  6 in total

Review 1.  Are Shorter Versions of the Positive and Negative Syndrome Scale (PANSS) Doable? A Critical Review.

Authors:  Jean-Pierre Lindenmayer
Journal:  Innov Clin Neurosci       Date:  2017-12-01

2.  Brief Clinical Assessment Scale for Schizophrenia (BCASS): Development, Validity, and Reliability Study.

Authors:  Mustafa Yildiz; Aysel Incedere; Mehmet Buğrahan Gürcan; Emre Osman
Journal:  Noro Psikiyatr Ars       Date:  2021-08-04       Impact factor: 1.339

3.  Evidence-based Shared-Decision-Making Assistant (SDM-assistant) for choosing antipsychotics: protocol of a cluster-randomized trial in hospitalized patients with schizophrenia.

Authors:  Stefan Leucht; Johannes Hamann; Spyridon Siafis; Nicola Bursch; Katharina Müller; Lisa Schmid; Florian Schuster; Jakob Waibel; Tri Huynh; Florian Matthes; Alessandro Rodolico; Peter Brieger; Markus Bühner; Stephan Heres
Journal:  BMC Psychiatry       Date:  2022-06-17       Impact factor: 4.144

4.  Bridging the Measurement Gap Between Research and Clinical Care in Schizophrenia: Positive and Negative Syndrome Scale-6 (PANSS-6) and Other Assessments Based on the Simplified Negative and Positive Symptoms Interview (SNAPSI).

Authors:  Søren D Østergaard; Mark G A Opler; Christoph U Correll
Journal:  Innov Clin Neurosci       Date:  2017-12-01

5.  Cognitive Enhancement Therapy vs social skills training in schizophrenia: a cluster randomized comparative effectiveness evaluation.

Authors:  Russell K Schutt; Haiyi Xie; Kim T Mueser; Matthew A Killam; Jonathan Delman; Shaun M Eack; Raquelle Mesholam-Gately; Sarah I Pratt; Luis Sandoval; Meghan M Santos; Laura R Golden; Matcheri S Keshavan
Journal:  BMC Psychiatry       Date:  2022-09-01       Impact factor: 4.144

6.  Scalability of the Positive and Negative Syndrome Scale in first-episode schizophrenia assessed by Rasch models.

Authors:  Lone Baandrup; Peter Allerup; Mette Ø Nielsen; Signe W Düring; Kirsten B Bojesen; Stefan Leucht; Silvana Galderisi; Armida Mucci; Paola Bucci; Celso Arango; Covadonga M Díaz-Caneja; Paola Dazzan; Philip McGuire; Arsime Demjaha; Bjørn H Ebdrup; Wolfgang W Fleischhacker; René S Kahn; Birte Y Glenthøj
Journal:  Acta Psychiatr Scand       Date:  2022-04-22       Impact factor: 7.734

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.